NGR-hTNf plus doxorubicin in recurrent ovarian cancer

Domenica Lorusso; Paola Malaguti; Giovanni Scambia; Claudio Bordignon; Francesco Raspagliesi

NGR-hTNf plus doxorubicin in recurrent ovarian cancer

Domenica Lorusso, Paola Malaguti, Giovanni Scambia, Claudio Bordignon, Francesco Raspagliesi

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article › peer-review

Abstract

Ovarian cancer is the most lethal gynaecological cancer. Despite surgery and first-line chemotherapy, tumours recur in 60-70% of cases and prognosis is poor. Several studies have indicated that the cytokine tumour necrosis factor (TNF) has antitumour activity when given systematically, but its high toxicity has limited its use. Peptides containing the aspargine-glycine-arginine motif (NGR peptides) selectively bind to the aminopeptidase N ligand CD13, which is overexpressed in the cells of tumour blood vessels. It has been found that the combination of an NGR peptide and human TNF (NGR-hTNF) has the ability to increase intratumoural doxorubicin distribution by altering the tumour vasculature. In this article, we describe the activity and toxicity profile of NGR-hTNF plus doxorubicin as a combination treatment for recurrent ovarian cancer.

Original language	English
Pages (from-to)	107-110
Number of pages	4
Journal	European Oncology and Haematology
Volume	8
Issue number	2
Publication status	Published - May 2012

Keywords

Doxorubicin
Ngr-hTNf
Platinum-resistant
Platinum-sensitive
Recurrent ovarian cancer

ASJC Scopus subject areas

Hematology
Oncology

Fingerprint Dive into the research topics of 'NGR-hTNf plus doxorubicin in recurrent ovarian cancer'. Together they form a unique fingerprint.

Cite this

@article{e964e0ff5f214656b467dc53a8fe876a,

title = "NGR-hTNf plus doxorubicin in recurrent ovarian cancer",

abstract = "Ovarian cancer is the most lethal gynaecological cancer. Despite surgery and first-line chemotherapy, tumours recur in 60-70% of cases and prognosis is poor. Several studies have indicated that the cytokine tumour necrosis factor (TNF) has antitumour activity when given systematically, but its high toxicity has limited its use. Peptides containing the aspargine-glycine-arginine motif (NGR peptides) selectively bind to the aminopeptidase N ligand CD13, which is overexpressed in the cells of tumour blood vessels. It has been found that the combination of an NGR peptide and human TNF (NGR-hTNF) has the ability to increase intratumoural doxorubicin distribution by altering the tumour vasculature. In this article, we describe the activity and toxicity profile of NGR-hTNF plus doxorubicin as a combination treatment for recurrent ovarian cancer.",

keywords = "Doxorubicin, Ngr-hTNf, Platinum-resistant, Platinum-sensitive, Recurrent ovarian cancer",

author = "Domenica Lorusso and Paola Malaguti and Giovanni Scambia and Claudio Bordignon and Francesco Raspagliesi",

year = "2012",

month = may,

language = "English",

volume = "8",

pages = "107--110",

journal = "European Oncology and Haematology",

issn = "2045-5275",

publisher = "Touch Digital Media",

number = "2",

}

TY - JOUR

T1 - NGR-hTNf plus doxorubicin in recurrent ovarian cancer

AU - Lorusso, Domenica

AU - Malaguti, Paola

AU - Scambia, Giovanni

AU - Bordignon, Claudio

AU - Raspagliesi, Francesco

PY - 2012/5

Y1 - 2012/5

N2 - Ovarian cancer is the most lethal gynaecological cancer. Despite surgery and first-line chemotherapy, tumours recur in 60-70% of cases and prognosis is poor. Several studies have indicated that the cytokine tumour necrosis factor (TNF) has antitumour activity when given systematically, but its high toxicity has limited its use. Peptides containing the aspargine-glycine-arginine motif (NGR peptides) selectively bind to the aminopeptidase N ligand CD13, which is overexpressed in the cells of tumour blood vessels. It has been found that the combination of an NGR peptide and human TNF (NGR-hTNF) has the ability to increase intratumoural doxorubicin distribution by altering the tumour vasculature. In this article, we describe the activity and toxicity profile of NGR-hTNF plus doxorubicin as a combination treatment for recurrent ovarian cancer.

AB - Ovarian cancer is the most lethal gynaecological cancer. Despite surgery and first-line chemotherapy, tumours recur in 60-70% of cases and prognosis is poor. Several studies have indicated that the cytokine tumour necrosis factor (TNF) has antitumour activity when given systematically, but its high toxicity has limited its use. Peptides containing the aspargine-glycine-arginine motif (NGR peptides) selectively bind to the aminopeptidase N ligand CD13, which is overexpressed in the cells of tumour blood vessels. It has been found that the combination of an NGR peptide and human TNF (NGR-hTNF) has the ability to increase intratumoural doxorubicin distribution by altering the tumour vasculature. In this article, we describe the activity and toxicity profile of NGR-hTNF plus doxorubicin as a combination treatment for recurrent ovarian cancer.

KW - Doxorubicin

KW - Ngr-hTNf

KW - Platinum-resistant

KW - Platinum-sensitive

KW - Recurrent ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=84866783735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866783735&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84866783735

VL - 8

SP - 107

EP - 110

JO - European Oncology and Haematology

JF - European Oncology and Haematology

SN - 2045-5275

IS - 2

ER -

NGR-hTNf plus doxorubicin in recurrent ovarian cancer

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Cite this